Treatment of supraventricular tachyarrhythmias with intravenous calcium channel blockers: Are subtle differences worth the cost?

Pharmacotherapy

Volumn 16, Issue 5 I, 1996, Pages 861-868

  Cheiman, Dina M ^a   Shea, Brian F ^a   Kelly, Ralph A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; VERAPAMIL;

BOLUS INJECTION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEMODYNAMICS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; REVIEW; SUPRAVENTRICULAR TACHYCARDIA;

CALCIUM CHANNEL BLOCKERS; CLINICAL TRIALS; DILTIAZEM; HEART RATE; HUMANS; INJECTIONS, INTRAVENOUS; TACHYCARDIA, SUPRAVENTRICULAR; VERAPAMIL;

EID: 0029764054     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Perry RS, Illsley SS. Basic cardiac electrophysiology and mechanisms of antiarrhythmic agents. Am J Hosp Pharm 1986;43:957-74.
2. Singh BN, Nademanee K, Baky SH. Calcium antagonists: clinical use in the treatment of arrhythmias. Drugs 1983;25:125-53.
3. Huycke EC, Sung RJ, Dias VC, Milstein S, Hariman RJ, Platia EV. Intravenous diltiazem for termination of reentrant supraventricular tachycardia: a placebo-controlled, randomized, double-blind, multicenter study. J Am Coll Cardiol 1989;13:538-44.
4. Ellenbogen KA, Dias VC, Plumb VJ, Heywood TJ, Mirvis DM. A placebo-controlled trial of continuous intravenous diltiazem infusion for 24-hour heart rate control during atrial fibrillation and atrial flutter: a multicenter study. J Am Coll Cardiol 1991;18:891-7.
5. Waxman HL, Myerburg RJ, Appel R, Sung RJ. Verapamil for control of ventricular rate in paroxysmal supraventricular tachycardia and atrial fibrillation or flutter. Ann Intern Med 1981;94:1-6.
6. Hayami H, Hiraoka M. Effects of diltiazem on patients with paroxysmal reentrant supraventricular tachycardia. Respiration Circulation 1987;35:433-9.
7. Barbarash RA, Bauman JL, Lukazewski AA, Srebro JP, Rich S. Verapamil infusions in the treatment of atrial tachyarrhythmias. Crit Care Med 1986;14:886-8.
8. Baky SH, Singh BN. Verapamil hydrochloride: pharmacologic properties and role in cardiovascular therapeutics. Pharmacotherapy 1982;2:328-53.
9. Bohm M, Schwinger RGH, Erdman E. Different cardiodepressant potency of various calcium channel antagonist in human myocardium. Am J Cardiol 1990;65:1039-41.
10. Schwinger RHG, Bohm M, Erdman E. Negative inotropic activity of the calcium antagonists isradipine, nifedipine, diltiazem, and verapamil in diseased human myocardium. Am J Hypertens 1991;4:185S-7.
11. Baughman KL. Calcium channel blocking agents in congestive heart failure. AmJ Med 1986;80(suppl 2B):46-50.
12. Triggle DJ. Sites, mechanisms of action, and differentiation of calcium channel antagonists. Am J Hypertens 1991;4:422S-9.
13. Marion Merrell Dow. Cardizem (diltiazem) injectable package insert. Kansas City, MO; 1991.
14. Knoll Pharmaceutical Company. Isoptin (verapamil) injectable package insert. Whippany, NJ; revised May 1990.
15. Ganz LI, Friedman PL. Supraventricular tachycardia. N Engl J Med 1995;332:162-73.
16. Katz AM, Leach NM. Differential effects of 1,4-dihydropyridine calcium channel blockers: therapeutic implications. J Clin Pharmacol 1987;27:825-34.
17. Murad F. Drugs used for the treatment of angina: organic nitrates, calcium channel blockers, and β-adrenergic antagonists. In: Gilman AG, Rall TW, Nies AS, Tayler P, eds. Goodman and Gilman's the pharmacological basis of therapeutics. New York: Pergamon Press, 1990:764-83.
18. Bigger JT, Hoffman BF. Antiarrhythmic drugs. In: Gilman AG, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's the pharmacological basis of therapeutics. New York: Pergamon Press, 1990:840-73.
19. American Heart Association, Emergency Cardiac Care Committee and Subcommittees. Guidelines for cardiopulmonary resuscitation and emergency cardiac care. III. Adult advanced cardiac life support. JAMA 1992;268(16): 2199-241.
20. Visken S, Belhassen B. Acute management of paroxysmal atrioventricular junctional reentrant supraventricular tachycardia: pharmacologic strategies. Am Heart J 1990;120:180-8.
21. DiMarco JP, Miles W, Akhtar M, et al. Adenosine for paroxysmal supraventricular tachycardia: dose ranging and comparison with verapamil: assessment in placebo-controlled, multicenter trials: the adenosine for PSVT study group. Ann Intern Med 1990;113:104-10.
22. Garratt C, Linker N, Griffith M, Ward D, Camm AJ. Comparison of adenosine and verapamil for termination of paroxysmal junctional tachycardia. Am J Cardiol. 1989;64: 1310-16.
23. Hutter AM Jr. Cardiac tachyarrhythmias: basic aspects and pharmacologic therapy. In: Rubenslein E, Federman D, eds. Scientific American Medicine. New York: Scientific American Inc., 1990:1-12.
24. Heywood JT, Graham B, Marais GE, Jutzy KR. Effects of intravenous diltiazem on rapid atrial fibrillation accompanied by congestive heart failure. AmJ Cardiol 1991;67:1150-2.
25. Goldenberg IF, Lewis WR, Dias VC, Heywood JT, Pedersen WR. Intravenous diltiazem for the treatment of patients with atrial fibrillation or flutter and moderate to severe congestive heart failure. Am J Cardiol 1994;74:884-9.
26. Trissel LA. Handbook of injectable drugs. Bethesda, MD: American Society of Hospital Pharmacists, 1992:913-14.
27. Frisolone JA. Continuous verapamil infusion. Drug Intell Clin Pharm 1989;23:1005-6.
28. Reiter M, Shand DG, Aanonsen LM, Wagoner R, McCarthy E, Pritchett EL. Pharmacokinetics of verapamil experience with a sustained intravenous infusion regimen. Am J Cardiol 1982;50:716-21.
29. Iberti TJ, Benjamin E, Paluch TA, Gentili DR, Gabrielson GV. Use of constant-infusion verapamil for the treatment of postoperative supraventricular tachycardia. Crit Care Med 1986;14:283-4.